P126 Neoadjuvant chemotherapy or cystectomy for muscle-invasive bladder cancer – an analysis of survival outcomes at a UK tertiary referral centre (original) (raw)

BJU International

Abstract

Introduction Neoadjuvant platinum combination chemotherapy has been shown to confer a survival benefit in patients with muscle invasive bladder cancer (MIBC) undergoing cystectomy. This survival benefit has to be nevertheless balanced against chemo-toxicity. We present our experience at a UK tertiary referral centre. Methods Patients undergoing cystectomy for MIBC between 2004–2011 were identified from a departmental database. Patients having neoadjuvant chemotherapy (gemcitibine/cisplatin) were identified by cross-checking with oncology records. Review of the records was carried out to identify demographic details, pathological findings at cystectomy and survival outcomes. Results We identified 192 patients with MIBC with complete datasets – 69 underwent neoadjuvant chemotherapy (NAC) and 123 underwent primary cystectomy (PC). The male:female ratio was 2.6:1 and median follow-up was 47 months. The overall median survival was 20 months. Kaplan Meier analysis showed an overall 5 year...

Edgar Paez hasn't uploaded this paper.

Let Edgar know you want this paper to be uploaded.

Ask for this paper to be uploaded.